Is Aclaris Therapeutics, Inc. (ACRS) a Buy, Sell, or Hold?
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
$5.6 USD
$0.17 (3.13%)
- Volume
- 6.08M
- Average Volume
- 1.67M
- Market Capitalization
- $675.33M
- P/E Ratio
- -10.00
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $5.85
- Year Low
- $1.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.03
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Neal S. Walker |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ACRS |
| CUSIP | 00461U105 |
| CIK | 0001557746 |
| Web | https://www.aclaristx.com |
| Phone | 484 324 7933 |
| Currency | USD |
| Employees | 73 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.03 |
| Quick Ratio | 4.03 |
| Cash Ratio | 1.05 |
Sales & Book Value
| Annual Sales | $7.83M |
| Price / Sales | 80.71 |
| Cash Flow | -0.41 |
| Price / Cash Flow | -12.92 |
| Price / Book | 5.02 |
Price Target and Rating
| Average Stock Price Forecast | $10.00 |
| High Stock Price Forecast | $12.00 |
| Low Stock Price Forecast | $10.00 |
| Forecast Upside/Downside | -44.00% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 16 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.53 |
| Trailing P/E Ratio | -10.00 |
| PEG Ratio | -0.19 |
| P/E Growth | -0.19 |
| Net Income | -$64.92M |
| Net Margin | -832.58% |
| Pretax Margin | -832.58% |
| Return on Equity | -55.89% |
| Return on Assets | -35.06% |
Financials Score
| AltmanZ Score | -0.24 |
| Piotroski Score | 2.00 |
| Working Capital | 82.86M |
| Total Assets | 198.72M |
| Ebit | -71.14M |
| Market Cap | 675.33M |
| Total Liabilities | 55.07M |
Poll Results
About Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI ... -1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
2026-07-01 09:26:05
Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
3 Penny Stocks Under $5 Backed by Real Revenue Growth
2026-06-23 17:35:16
Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
3 Penny Stocks Under $5 Backed by Real Revenue Growth
2026-06-20 09:20:27
Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
2026-06-04 15:03:33
Aclaris Therapeutics NASDAQ: ACRS executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting upcoming readouts across its immunology pipeline and a planned Phase 2 asthma study for its lead bispecific antibody.
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-28 08:30:00
WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference in New York, NY. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com.
2026-05-14 14:30:46
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
2026-05-08 08:30:00
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday May 14, 2026, at 9:35 AM PT, Aclaris' President and Chief Operating Officer Dr. Hugh Davis will provide a corporate presentation during the 2026 Bank of America Healthcare Conference in Las Vegas, NV. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com.
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 09:51:08
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.12 per share a year ago.
Frequently Asked Questions
-
What is the current Aclaris Therapeutics, Inc. (ACRS) stock price?
-
Aclaris Therapeutics, Inc.(NASDAQ:ACRS) stock price is $5.6 in the last trading session. During the trading session, ACRS stock reached the peak price of $5.85 while $1.46 was the lowest point it dropped to. The percentage change in ACRS stock occurred in the recent session was 3.13% while the dollar amount for the price change in ACRS stock was $0.17.
-
ACRS's industry and sector of operation?
-
The NASDAQ listed ACRS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ACRS?
-
Matthew Rothman | General Counsel & Corporate Secretary
Nina Samra | Senior Vice President of Clinical Operations
James Loerop | Chief Business Officer
Kevin Balthaser | Chief Financial Officer
Steve Tucker | Executive Vice President of Project Leadership -
How many employees does ACRS have?
-
Number of ACRS employees currently stands at 73. ACRS operates from 640 Lee Road, Wayne, PA 19087, US.
-
Link for ACRS official website?
-
Official Website of ACRS is: https://www.aclaristx.com
-
How do I contact ACRS?
-
ACRS could be contacted at phone #484 324 7933 and can also be accessed through its website. ACRS operates from 640 Lee Road, Wayne, PA 19087, US.
-
How many shares of ACRS are traded daily?
-
The average number of ACRS shares traded daily for last 3 months was 1.67M.
-
What is the market cap of ACRS currently?
-
The market value of ACRS currently stands at $675.33M with its latest stock price at $5.6